Transdermal Skin Patches Market 2022-2028

Description

List of Tables

Global Transdermal Skin Patches Market Size, Share and Trends Analysis Report, By Type (Single-Layer Drug-in-Adhesive, Multi-layer Drug-in-Adhesive, Matrix, and Others), By Application (Pain Relief, Smoking Reduction and Cessation Aid, Overactive Bladder, Hormonal Therapy, and Others), Forecast (2022-2028)

The global serine protein kinase market is anticipated to grow at a significant CAGR of around 4.5% during the forecast period (2022-2028). The major factors such as the increasing advantages of transdermal medicine over oral and ingesting medications for gastrointestinal toxicity which results in nausea and vomiting are attributed to the growth of the market. Also, factors such as non-permeability of the skin among the patients to absorb a range of medication with the development of contact of dermatitis at the site of application of transdermal patches can limit the growth of the market. The main advantage is that the patch provides a controlled release of the drug to the patient, usually through a perforated membrane covering the drug reservoir. For treatment such as migraine, hormones, pain, cardiovascular diseases these patches are also used. Transdermal skin patches are being marketed that can be worn anywhere from as little as eight hours to as long as seven days depending upon the indication by the doctors. Therefore, this advancement in patches would drive the global transdermal skin patches market in the forecast period. For instance, in Sept 2021, Luye Pharma announced that it has received approval for Rivastigmine Multi-Day Transdermal Patch by the UK's Medicines and Healthcare Products Regulatory Agency.

The global transdermal skin patches market is segmented based on the type and application. Based on the type the market is sub-segmented into single-layer drugs in adhesive, multi-layer drug-in-adhesive, matrix, and others. Based on the application the market is sub-segmented into pain relief, smoking reduction and cessation aid, overactive bladder, hormonal therapy, and others. The above-mentioned segments can be customized as per the requirements. These patches deliver medication dose through the skin using diffusion technique which later gets released in the bloodstream over a long period. For instance, in June 2020, Vektor Pharma TF GmbH launched a generic version of the transdermal Neupro patch (Rotigotine), often used to ease the symptoms of Parkinson's disease.

Geographically market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is anticipated to hold a considerable share in the market owing to the presence of key players and established healthcare infrastructure. Government initiatives and an increase in the number of research partnerships are expected to increase the market's growth. Lung cancer is the leading cause of cancer death in men and women due to smoking. Technologies supporting transdermal patches are being enhanced with any issue to make them more adaptable and popular in the United States. Major companies in the market are increasingly opting for acquisitions and collaborations to enhance and expand the transdermal skin patches market. For instance, in April 2020, BASF SE launched 'Sacred Patch' a new skincare active ingredient that helps boost emotional well-being.

The major companies serving the global transdermal skin patches market include Novartis International AG, Teva Pharmaceuticals USA Inc., The 3M Co., Mylan N.V., Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers& acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, Canon Inc, a Delaware-based healthcare pharmaceuticals firm, purchased ProSolus Inc in 2019 to strengthen its position and develop new transdermal treatment. ProSolus Inc is a pharmaceutical company based in the US that specializes in transdermal solutions.

Research Methodology

The market study of the global transdermal skin patches market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

Financial reports of companies involved in the market.
Whitepapers, research papers, and news blogs.
Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Transdermal Skin Patches Market by Type

2. Global Transdermal Skin Patches Market by Application

The Report Covers:

Comprehensive Research Methodology of the global transdermal skin patches market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global transdermal skin patches market.
Insights about market determinants that are stimulating the global transdermal skin patches market.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: OMR2026026

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the Global Transdermal Skin Patches Market
Recovery Scenario of Global Transdermal Skin Patches Market
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Type
- 1.2.2. BY Application

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Teva Pharmaceuticals USA Inc
- 3.1.1. Overview
- 3.1.2. Financial Analysis
- 3.1.3. SWOT Analysis
- 3.1.4. Recent Developments
3.2. The 3M Co
- 3.2.1. Overview
- 3.2.2. Financial Analysis
- 3.2.3. SWOT Analysis
- 3.2.4. Recent Developments
3.3. Novartis International AG
- 3.3.1. Overview
- 3.3.2. Financial Analysis
- 3.3.3. SWOT Analysis
- 3.3.4. Recent Developments
3.4. Mylan N.V
- 3.4.1. Overview
- 3.4.2. Financial Analysis
- 3.4.3. SWOT Analysis
- 3.4.4. Recent Developments
3.5. Pfizer Inc
- 3.5.1. Overview
- 3.5.2. Financial Analysis
- 3.5.3. SWOT Analysis
- 3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players

4. Market Segmentation

4.1. Global Transdermal Skin Patches Market by Type
- 4.1.1. Single Layer Drug-in-Adhesive
- 4.1.2. Multi-Layer Drug-in-Adhesive
- 4.1.3. Matrix
- 4.1.4. Others
4.2. Global Transdermal Skin Patches Market by Application
- 4.2.1. Pain Relief
- 4.2.2. Smoking Reduction & Cessation Aid
- 4.2.3.
- 4.2.4. Overactive Bladder
- 4.2.5. Hormonal Therapy
- 4.2.6. Others

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

5.4.1 Latin America

5.4.2 Middle East and Africa

6. Company Profiles

6.1. InteRNA Technologies B.V.
6.2. Novartis AG
6.3. OrchidPharma Ltd
6.4. Apotex Inc
6.5. Alembic Ltd
6.6. Cadila Pharmaceuticals
6.7. Aurobindo Pharma Ltd
6.8. Ajanta Pharma Ltd
6.9. AdhexPharma
6.10. Macleods Pharmaceuticals Ltd
6.11. Dr. Reddy's Laboratories Ltd
6.12. Pfizer Inc
6.13. Mylan N.V
6.14. Teikoku Pharma USA Inc.
6.15. Luye Pharma Group
6.16. Purdue Pharma Manufacturing LP